Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin

American Heart Journal
Evan A SteinEzetimibe Study Group

Abstract

Despite the efficacy of statins in lowering low-density lipoprotein cholesterol (LDL-C) levels, many patients who are at high risk for heart disease with hypercholesterolemia require additional LDL-C level reduction. The cholesterol absorption inhibitor, ezetimibe, has been shown to provide significant incremental reductions in LDL-C levels when co-administered with statins. This study was performed to compare the efficacy and safety of ezetimibe (10 mg) plus response-based atorvastatin titration versus response-based atorvastatin titration alone in the attainment of LDL-C goals in subjects who are at high risk for coronary heart disease (CHD) and are not at their LDL-C goal on the starting dose of atorvastatin. This was a 14-week, multicenter, randomized, double-blind, active-controlled study conducted in 113 clinical research centers in 21 countries. Participants were adults with heterozygous familial hypercholesterolemia (HeFH), CHD, or multiple (> or =2) cardiovascular risk factors, and a LDL-C level > or =130 mg/dL after a 6- to 10-week dietary stabilization and atorvastatin (10 mg/day) open-label run-in period. Eligible subjects continued to receive atorvastatin (10 mg) and were randomized to receive blinded treatment wit...Continue Reading

References

Aug 12, 1999·The New England Journal of Medicine·J Genest, M A Lavoie
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Nov 9, 2002·The American Journal of Cardiology·Claude GagnéUNKNOWN Ezetimibe Study Group
Dec 31, 2002·Journal of the American College of Cardiology·Michael H DavidsonEnrico P Veltri
Feb 15, 2003·The American Journal of Cardiology·Boris KerznerUNKNOWN Ezetimibe Study Group
Nov 26, 2003·The American Journal of Cardiology·Evan A SteinUNKNOWN HeFH Study Group
Jan 22, 2004·The European Journal of General Practice·Carlos BrotonsUNKNOWN International Society of Behavioral Medicine
Nov 9, 2004·Atherosclerosis. Supplements·T R PedersenUNKNOWN Scandinavian Simvastatin Survival Study Group

❮ Previous
Next ❯

Citations

Nov 26, 2010·Current Atherosclerosis Reports·Carlos A DujovneMatthew K Ito
Jan 16, 2007·Current Neurology and Neuroscience Reports·J David Spence
Jul 5, 2005·The American Journal of Cardiology·Nilo B CaterScott M Grundy
Aug 30, 2008·The Journal of Cardiovascular Nursing·Kathleen Berra
Nov 9, 2005·Current Opinion in Lipidology·Eyal LeibovitzDov Gavish
Jul 17, 2010·American Journal of Therapeutics·Srikanth KatragaddaRohit Arora
May 29, 2010·Current Opinion in Lipidology·Maartje E VisserErik S G Stroes
May 9, 2013·Current Opinion in Lipidology·Michel Farnier
Jan 5, 2008·International Journal of Clinical Practice·M FlorentinM S Elisaf
Aug 24, 2011·Lipids in Health and Disease·Beth L AbramsonAndrew M Tershakovec
Nov 12, 2013·Lipids in Health and Disease·Ioanna XanthopoulouDimitrios Alexopoulos
Jun 15, 2007·Lipids in Health and Disease·Matthew T BennettGregory P Bondy
Feb 27, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Kiranbir JosanFinlay A McAlister
Jul 17, 2008·Vascular Health and Risk Management·Navin K KapurRoger S Blumenthal
Dec 4, 2010·Vascular Health and Risk Management·Ian Hamilton-CraigStan Woodhouse
May 31, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michel Farnier
Aug 7, 2010·Physical Therapy·Stephanie L Di StasiStuart A Binder-Macleod
Jun 15, 2010·Journal of Atherosclerosis and Thrombosis·José C SandovalShizuya Yamashita
Jan 16, 2014·Annual Review of Medicine·Evan A Stein, Frederick Raal
Jul 17, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Na LiYue-Jin Yang
Nov 30, 2014·Endocrinology and Metabolism Clinics of North America·Evan A Stein, Frederick J Raal
Mar 20, 2015·Journal of Medical Economics·Pedro A LairesGlenn Davies
Nov 16, 2006·Expert Opinion on Therapeutic Targets·Irene F Gazi, Dimitri P Mikhailidis
Nov 30, 2012·Expert Review of Cardiovascular Therapy·Marybeth U Allian-Sauer, James M Falko
Dec 22, 2007·Expert Review of Cardiovascular Therapy·Luis Rodríguez Padial
Oct 17, 2006·Expert Opinion on Investigational Drugs·John R Burnett, Murray W Huff
Jun 10, 2008·Expert Opinion on Emerging Drugs·Raghda K Elsayed, Jeffery D Evans
Mar 30, 2005·Expert Opinion on Drug Safety·Rodrigo AlonsoPedro Mata
Apr 1, 2006·Current Medical Research and Opinion·Stella S Daskalopoulou, Dimitri P Mikhailidis
Nov 10, 2009·Current Medical Research and Opinion·Erkki J O SoiniLeo Niskanen

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.